

JUL. 13. 2004 2:59PM

OFFICIAL  
AVENTIS US PATENT  
DEPARTMENT

RECEIVED  
CENTRAL FAX CENTER

NO. 5285 P. 1

JUL 12 2004

FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE

Applicants Docket Number:  
USST98032 US PCT

Applicants:  
BRANELLEC, et al.

Serial No.  
09/787,995

Filing Date:  
July 9, 2001

Title of Invention:

USE OF SPECIFIC HYBRID PROMOTERS FOR CONTROLLING TISSUE EXPRESSION

CERTIFICATE OF TRANSMISSION	
I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, Maria Marvich, at 703-672-9306, on	
Date of Deposit	July 13, 2004
Printed Name of Person Signing Certificate Jonas Pierre, Sr.	
Signature	

Total Number of Pages Sent: 7

Attorney: F. Aaron Dubberley  
Reg. No. 41,001  
Group Art Unit: 1636  
Examiner: MARVICH, Maria

TO: Mail Stop Patent Application  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- |   |  |
|---|--|
| <input checked="" type="checkbox"/> Response to Office Action (4 - pages) | <input type="checkbox"/> Fee Transmittal             |
| <input checked="" type="checkbox"/> Notice Of Appeal (1 - page)           | <input type="checkbox"/> Petition under 37 CFR _____ |
| <input checked="" type="checkbox"/> Extension of Time Petition (1 - page) | <input type="checkbox"/> Other _____                 |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order            | <input type="checkbox"/> Other _____                 |
| <input type="checkbox"/> Maintenance Fee Transmittal                      |  |

Receipt Confirmed:

Signed

Dated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com  
NOTICE: The documents accompanying this teletype transmission are intended only for the use of the individual or entity named above. If you have received this teletype in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

JUL. 13. 2004 2:59PM

AVENTIS US PAT DEPT

RECEIVED  
CENTRAL FAX CENTER

NO. 5285

P. 2

JUL 12 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
**BRANELLEC, et al.**

Examiner: MARVICH, Maria

Application No.: 09/787,995

Art Unit: 1636

Filed: July 9, 2001

TELEFAX CERTIFICATE

Title: **USE OF SPECIFIC HYBRID  
PROMOTERS FOR CONTROLLING  
TISSUE EXPRESSION**

I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, Alexandria, VA 22313, on

July 13, 2004

Date of transmission

Signature

*[Signature]*

RESPONSE TO OFFICE ACTION

Mail Stop Patent Application  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In further response to the final Office Action dated February 13, 2004 and in response to the Advisory Action dated June 09, 2004 for the above-identified application, Applicants respectfully request withdrawal of the finality of the Office Action and traverse all rejections of the claims. In case Applicants' request is not granted, Applicants enclose a Notice of Appeal, to maintain pendency and prevent abandonment of the application. The Commissioner is authorized to charge any additional fees or credit any overpayment necessitated by this response to Deposit Account No. 18-1982.

Applicants wish to thank Examiner Marvich for her time discussing this case with others in the Patent Office after issuance of the Advisory Action and particularly for the phone message she left with the undersigned on June 22, 2004. In this message, the Examiner indicated that she would reconsider withdrawing the finality of the Office Action and her reliance on the vector maps first presented in the final Office Action, if Applicants would submit a further response reiterating their arguments. Such a response follows.

Applicants respectfully request that the finality of the February 13, 2004 Office Action be withdrawn and a new Office Action be issued. Applicants have had no opportunity to evaluate or